Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Cingulate Inc ( (CING) ).
Cingulate Inc. announced changes to its board structure as part of an effort to streamline governance, with Class II directors Jeff Ervin and Jay Roberts deciding not to seek re-election when their terms end at the 2026 Annual Meeting of Stockholders. On the date of the meeting, the company plans to reduce the board size to five directors and appoint a new chairman, signaling a more focused leadership framework.
To comply with its certificate of incorporation, which requires each director class to represent roughly one-third of the total board, director Jeff Hargroves agreed to resign as a Class I director and be reappointed as a Class II director. On May 18, 2026, the board accepted his resignation, immediately reappointed him as a Class II director, and nominated him for election at the upcoming Annual Meeting, leaving Class I directors Peter Werth and Frederick Jiang in place and clarifying the company’s board composition for investors.
The most recent analyst rating on (CING) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
The score is held down primarily by weak financial performance (no revenue, recurring losses, leverage concerns, and ongoing cash-burn history) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some support through improved access to capital and governance updates, but that benefit is tempered by dilution risk; valuation metrics offer limited insight due to negative earnings and no dividend.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Cingulate Inc. operates in the biopharmaceutical sector, focusing on developing and commercializing treatments for central nervous system and related disorders. The company targets niche and underserved patient populations, positioning its pipeline and governance structure to support long-term growth and regulatory execution in highly competitive therapeutic markets.
Average Trading Volume: 527,102
Technical Sentiment Signal: Sell
Current Market Cap: $60.67M
Find detailed analytics on CING stock on TipRanks’ Stock Analysis page.